PMID- 31672434
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 119
IP  - 6
DP  - 2020 Jun
TI  - Therapeutic drug monitoring of the teicoplanin trough level after the loading 
      doses in patients receiving venoarterial extracorporeal membrane oxygenation.
PG  - 1086-1092
LID - S0929-6646(19)30624-2 [pii]
LID - 10.1016/j.jfma.2019.10.005 [doi]
AB  - BACKGROUND: The optimal loading dose of teicoplanin in patients receiving 
      venoarterial extracorporeal membrane oxygenation (VA-ECMO) has never been 
      determined by therapeutic drug monitoring. This study investigated the 
      appropriateness of proposed loading dose regimens of teicoplanin when 
      administered to patients receiving VA-ECMO by using a previously proposed loading 
      dosage and measuring the teicoplanin trough concentration (C(trough)). METHODS: 
      Patients who initiated teicoplanin therapy while receiving VA-ECMO were enrolled. 
      Every included patient received four loading doses of teicoplanin at a dose of 
      12 mg/kg. The first three doses were administered 12 h apart, and the fourth dose 
      was administered 24 h after the third dose. Blood samples were collected before 
      administering the maintenance dose (i.e., the fifth dose), and the teicoplanin 
      C(trough) was measured. Serum teicoplanin levels were determined using an Agilent 
      1290 ultra-high performance liquid chromatography system. RESULTS: The 
      teicoplanin C(trough) was successfully tested in 11 patients. Their median age 
      was 68.2 years, and 81.8% of them were men. The median of each loading dose was 
      11.6 (range, 10.7-12.8) mg/kg. The median teicoplanin C(trough) was 22.01 (range, 
      14.85-44.84) mg/L. All patients had a C(trough) of more than 10 mg/L, whereas 
      90.9% (10/11) of the patients achieved a C(trough) of more than 15 mg/L. 
      CONCLUSION: The loading dosage consisting of four doses of teicoplanin 
      administered within the first 72 h at a dose of 12 mg/kg/dose could achieve an 
      adequate therapeutic C(trough) of teicoplanin in patients receiving VA-ECMO.
CI  - Copyright (c) 2019 Formosan Medical Association. Published by Elsevier B.V. All 
      rights reserved.
FAU - Chen, Guan-Jhou
AU  - Chen GJ
AD  - Department of Internal Medicine, National Taiwan University Hospital Yun-Lin 
      Branch, Yunlin County, Taiwan.
FAU - Lin, Shu-Wen
AU  - Lin SW
AD  - Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan 
      University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University 
      Hospital, Taipei, Taiwan; School of Pharmacy, College of Medicine, National 
      Taiwan University, Taipei, Taiwan.
FAU - Tsai, I-Lin
AU  - Tsai IL
AD  - Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical 
      University, Taipei, Taiwan; Department of Biochemistry and Molecular Cell 
      Biology, School of Medicine, College of Medicine, Taipei Medical University, 
      Taipei, Taiwan.
FAU - Kuo, Ching-Hua
AU  - Kuo CH
AD  - Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan; 
      School of Pharmacy, College of Medicine, National Taiwan University, Taipei, 
      Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National 
      Taiwan University, Taipei, Taiwan.
FAU - Wang, Jann-Tay
AU  - Wang JT
AD  - Section of Infectious Diseases, Department of Internal Medicine, National Taiwan 
      University Hospital, College of Medicine, National Taiwan University, Taipei, 
      Taiwan.
FAU - Hsieh, Szu-Min
AU  - Hsieh SM
AD  - Section of Infectious Diseases, Department of Internal Medicine, National Taiwan 
      University Hospital, College of Medicine, National Taiwan University, Taipei, 
      Taiwan. Electronic address: hsmaids@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20191028
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (Anti-Bacterial Agents)
RN  - 61036-62-2 (Teicoplanin)
SB  - IM
MH  - Aged
MH  - *Anti-Bacterial Agents/pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Drug Monitoring
MH  - *Extracorporeal Membrane Oxygenation
MH  - Female
MH  - Humans
MH  - Male
MH  - *Teicoplanin/pharmacokinetics
OTO - NOTNLM
OT  - Glycopeptides
OT  - Nephrotoxicity
OT  - Pharmacokinetics
OT  - Teicoplanin
OT  - Therapeutic drug monitoring
COIS- Declaration of Competing Interest The authors have no conflicts of interest 
      relevant to this article.
EDAT- 2019/11/02 06:00
MHDA- 2021/02/16 06:00
CRDT- 2019/11/02 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2019/09/03 00:00 [revised]
PHST- 2019/10/04 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2019/11/02 06:00 [entrez]
AID - S0929-6646(19)30624-2 [pii]
AID - 10.1016/j.jfma.2019.10.005 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2020 Jun;119(6):1086-1092. doi: 10.1016/j.jfma.2019.10.005. 
      Epub 2019 Oct 28.